Next Article in Journal
Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination
Next Article in Special Issue
Mechanisms of Metastatic Tumor Dormancy and Implications for Cancer Therapy
Previous Article in Journal
Growth and Metabolic Response of Chinese Perch to Different Dietary Protein-to-Energy Ratios in Artificial Diets
Previous Article in Special Issue
Ceritinib-Induced Regression of an Insulin-Like Growth Factor-Driven Neuroepithelial Brain Tumor
Due to scheduled maintenance work on our core network, there may be short service disruptions on this website between 16:00 and 16:30 CEST on September 25th.
Case Report

Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports

1
Department of Oncology, Transplantation and New technologies in Medicine, University of Pisa, 56100 Pisa, Italy
2
Section of Statistics, University Hospital of Pisa, 56100 Pisa, Italy
3
Department of Clinical and Experimental Medicine, University of Pisa, 56100 Pisa, Italy
*
Author to whom correspondence should be addressed.
retired.
Int. J. Mol. Sci. 2019, 20(23), 5986; https://doi.org/10.3390/ijms20235986
Received: 30 October 2019 / Revised: 20 November 2019 / Accepted: 25 November 2019 / Published: 28 November 2019
This article summarizes the histories of six patients with different solid tumors treated with a new strategy based on tumor burden reduction and immune evasion as potential targets. All six patients were at a high risk of relapse and were likely to have a minimal residual disease following conventional therapy: biochemical recurrence (BCR) following radical prostatectomy (RP) (two prostate cancers patients), removal of distant metastases (one colorectal and one breast cancer), and complete response (CR) of distant metastases to conventional therapy (one breast cancer and one esophageal–gastric junction cancer). Four of the patients, two after RP and BCR, one after removal of a single pulmonary metastasis from breast cancer, and one after CR to chemotherapy of peritoneal metastases and ascites from an esophageal–gastric junction primary cancer, regularly received cycles of a new drug schedule with the aim of inhibiting immune suppression (IT). In these four patients, preliminary laboratory tests of peripheral blood suggested an interleukin (IL)-2/IL-12 mediated stimulation of cellular immune response with a concomitant decrease in vascular endothelial growth factor (VEGF) immune suppression. The fifth case was a breast cancer patient with distant metastases in CR, while receiving beta-interferon and interleukin-2 in addition to conventional hormone therapy. To date, all five patients are alive and doing well and they have been unexpectedly disease-free for 201 and 78 months following BCR, 28 months following the removal of a single pulmonary metastases, 32 months following CR to chemotherapy of peritoneal metastases and ascites, and 140 months following diagnosis of multiple bone metastases, respectively. The sixth patient, who had colorectal cancer and multiple synchronous liver metastases and underwent nine surgical interventions for metastatic disease, although not disease-free, is doing well 98 months after primary surgery. Our six cases reports can be interpreted with the hypothesis that immune manipulation and/or a concomitant low tumor burden favored their clinical outcome. View Full-Text
Keywords: advanced solid cancer; tumor burden; minimal residual disease; immune evasion; immunotherapy advanced solid cancer; tumor burden; minimal residual disease; immune evasion; immunotherapy
MDPI and ACS Style

Nicolini, A.; Ferrari, P.; Morganti, R.; Carpi, A. Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports. Int. J. Mol. Sci. 2019, 20, 5986. https://doi.org/10.3390/ijms20235986

AMA Style

Nicolini A, Ferrari P, Morganti R, Carpi A. Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports. International Journal of Molecular Sciences. 2019; 20(23):5986. https://doi.org/10.3390/ijms20235986

Chicago/Turabian Style

Nicolini, Andrea, Paola Ferrari, Riccardo Morganti, and Angelo Carpi. 2019. "Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports" International Journal of Molecular Sciences 20, no. 23: 5986. https://doi.org/10.3390/ijms20235986

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop